Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience

BackgroundBoth abiraterone and enzalutamide have shown to improve overall survival (OS), progression-free survival (PFS) and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of previous treatment with chemotherapy (COU-AA301...

Full description

Bibliographic Details
Main Authors: Rachel Raju, Arvind Sahu, Myron Klevansky, Javier Torres
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
real world
regional
metastatic prostate cancer
abiraterone
enzalutamide
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.656146/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.656146/full

Similar Items